Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

References for PMC Articles for PubMed (Select 18357341)


In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.

Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S.

J Exp Med. 2007 Feb 19;204(2):345-56. Epub 2007 Jan 29.


Random migration precedes stable target cell interactions of tumor-infiltrating T cells.

Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG, Weninger W.

J Exp Med. 2006 Nov 27;203(12):2749-61. Epub 2006 Nov 20.


Cancer regression in patients after transfer of genetically engineered lymphocytes.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.

Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.


Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation.

Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH.

Immunity. 2006 Jul;25(1):129-41.


Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses.

Wiedemann A, Depoil D, Faroudi M, Valitutti S.

Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10985-90. Epub 2006 Jul 10.


Adoptive immunotherapy for cancer: building on success.

Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP.

Nat Rev Immunol. 2006 May;6(5):383-93. Review.


Solid tumors "melt" from the inside after successful CD8 T cell attack.

Blohm U, Potthoff D, van der Kogel AJ, Pircher H.

Eur J Immunol. 2006 Feb;36(2):468-77.


T cells targeted against a single minor histocompatibility antigen can cure solid tumors.

Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C.

Nat Med. 2005 Nov;11(11):1222-9. Epub 2005 Oct 16.


Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.

Koneru M, Schaer D, Monu N, Ayala A, Frey AB.

J Immunol. 2005 Feb 15;174(4):1830-40.


Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T.

J Exp Med. 2005 Jan 17;201(2):249-57.


The three Es of cancer immunoediting.

Dunn GP, Old LJ, Schreiber RD.

Annu Rev Immunol. 2004;22:329-60. Review.


Bystander elimination of antigen loss variants in established tumors.

Spiotto MT, Rowley DA, Schreiber H.

Nat Med. 2004 Mar;10(3):294-8. Epub 2004 Feb 22.


Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. Epub 2002 Nov 11.


Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.


Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer.

Tyas L, Brophy VA, Pope A, Rivett AJ, Tavaré JM.

EMBO Rep. 2000 Sep;1(3):266-70.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk